



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07K 14/00		A2	(11) International Publication Number: WO 98/28331 (43) International Publication Date: 2 July 1998 (02.07.98)
(21) International Application Number: PCT/US97/23405 (22) International Filing Date: 22 December 1997 (22.12.97)		(81) Designated States: CA, JP, MX, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>Without international search report and to be republished upon receipt of that report.</i>	
(30) Priority Data: 08/771,737 20 December 1996 (20.12.96) US			
(71) Applicant: ABBOTT LABORATORIES [US/US]; CHAD 0377/AP6D-2, 100 Abbott Park Road, Abbott Park, IL 60064-3500 (US).			
(72) Inventors: BRIGGS, Clark, A.; 2280 Shannondale, Libertyville, IL 60048 (US). GOPALAKRISHNAN, Murali; 1568 Oxford Circle, Grayslake, IL 60030 (US). MCKENNA, David, G.; 3404 Cove court, McHenry, IL 60050 (US). MONTEGGIA, Lisa, M.; Apartment 2A, 239 Dittmer, Lindenhurst, IL 60046 (US). ROCH, Jean-Marc; Apartment 109, 1020 Lakehurst Drive, Waukegan, IL 60085 (US). SULLIVAN, James, P.; 705 Dimmeydale Drive, Deerfield, IL 60015 (US). TOUMA, Edward; 3313 Beacon Street #204, North Chicago, IL 60064 (US).			
(74) Agents: DANCKERS, Andreas, M. et al.; Abbott Laboratories, CHAD 0377/AP6D-2, 100 Abbott Park Road, Abbott Park, IL 60064-3500 (US).			
(54) Title: A VARIANT HUMAN ALPHA-7 ACETYLCHOLINE RECEPTOR SUBUNIT, AND METHODS OF PRODUCTION AND USE THEREOF			
(57) Abstract <p>A variant human $\alpha 7$ nicotinic acetylcholine receptor (nAChR) polypeptide is provided wherein the variant contains an amino acid substitution at the valine-274 position of the wild-type human $\alpha 7$ nAChR. Nucleic acid molecules encoding the variant human $\alpha 7$ nAChR, vectors and host cells containing such nucleic acid molecules are also provided. In addition, methods are provided for producing the variant as are methods of using such variants for screening compounds for activity at the nAChR.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

A VARIANT HUMAN ALPHA-7 ACETYLCHOLINE RECEPTOR SUBUNIT,
AND METHODS OF PRODUCTION AND USE THEREOF

Technical Field

5 The invention relates generally to receptor proteins and to DNA and RNA molecules encoding therefor. In particular, the invention relates to a variant human α 7 subunit in which there is a substitution of the valine-274 position of the wild-type human α 7 subunit. The invention also relates to DNA and RNA molecules that encode the variant human α 7 subunit, as well as to methods of using the variant subunit to identify compounds that interact with it.

10

Background of the Invention

This background considers the α 7 subunit as it relates to the nicotinic acetylcholine receptor (nAChR). The nAChR is comprised of transmembrane polypeptide subunits that form a cation-selective ion channel gated by acetylcholine (ACh) and other ligands. The 15 hydrophobic transmembrane M2 ("TM-2") region from each subunit is believed to form the wall of the ion channel.

Two of the more prominent nAChRs in brain are those containing α 4 subunits and those containing α 7 subunits (Sargent (1993) *Annu. Rev. Neurosci.* 16:403-443; Court *et al.* (1995) *Alzheimer Disease and Associated Disorders* 9:6-14). Mutations of the α 4 and α 7 20 subunits may underlie some diseases of the nervous system. For example, mutations of the α 4 subunit have been associated with some forms of epilepsy (Beck *et al.* (1994) *Neurobiol. Disease* 1:95-99; Steinlein *et al.* (1995) *Nature Genetics* 11:201-203). Additionally, α 7-containing nAChR may be involved in sensory processing related to schizophrenia (Freedman *et al.* (1995) *Biol. Psych.* 38:22-33; Rollins *et al.* (1995) *Schizophr. Res.* 15:183; Stevens *et al.* (1995) *Psychopharmacol.* 119:163-170), cytoprotection (Donnelly-Roberts *et al.* 25 (1996) *Brain Res.* 719:36-44; Akaike *et al.* (1994) *Brain Res.* 644:181-187; Martin *et al.* (1994) *Drug Dev. Res.* 31:135-141; Quik *et al.* (1994) *Brain Res.* 655:161-167), and neurite growth and innervation (Chan *et al.* (1993) *Neurosci.* 56:441-451; Pugh *et al.* (1994) *J. Neurosci.* 14:889-896; Freeman (1977) *Nature* 269:218-222; Broide *et al.* (1995) *Neurosci.* 30 67:83-94).

A splice variant involving the TM-2 region of the α 7 subunit has been detected in bovine chromaffin cells (García-Guzmán *et al.* (1995) *Eur. J. Neurosci.* 7:647-655), and a naturally-occurring mutation of a protein homologous to the α 7 subunit found in *Caenorhabditis elegans*, leads to neurodegeneration (Treinin *et al.* (1995) *Neuron* 14:871-877). 35 The latter is a single amino acid mutation in the TM-2 region similar to the chick α 7 valine-251 to threonine ("c- α 7V251T") mutation, one of several mutations artificially introduced into the

chick $\alpha 7$ subunit to facilitate the study of $\alpha 7$ nAChR structure and subunit function (Bertrand *et al.* (1995) *Sem. Neurosci.* 7:75-90).

Compared to the chick $\alpha 7$ wild-type ("c- $\alpha 7$ WT") nAChR, c- $\alpha 7$ V251T (also referred to as $\alpha 7-4$) retained high calcium permeability but desensitized slowly, and was 180-fold more sensitive to ACh. In addition, the c- $\alpha 7$ V251T nAChR responded to dihydro- β -erythroidine ("DH β E"), normally an nAChR antagonist at $\alpha 7$ and other wild-type nAChR, as if it were an agonist (Galzi *et al.* (1992) *Nature* 359:500-505; Bertrand *et al.* (1993) *Proc. Natl. Acad. Sci. USA* 90:6971-6975). These studies have led to a model delineating the structure of the pore-lining TM-2 region, and the hypothesis that specific mutations within the TM-2 region can generate ligand-gated ion channels that conduct current in the receptor-desensitized state in addition to the normal receptor-activated state (Bertrand *et al.* (1995), *supra*; Bertrand *et al.* (1992) *Proc. Natl. Acad. Sci. USA* 89:1261-1265; Galzi *et al.* (1995) *Neuropharmacol.* 34:563-582).

Although the chick $\alpha 7$ nAChR is pharmacologically similar to the mammalian $\alpha 7$ nAChR, there are significant differences. For example, 1,1-dimethyl-4-phenylpiperazinium ("DMPP") is a very weak partial agonist in the chick $\alpha 7$ nAChR, but is a highly efficacious agonist at the human $\alpha 7$ nAChR (Peng *et al.* (1994) *Mol. Pharmacol.* 45:546-554). Despite these differences, it would be expected that amino acid changes in the human $\alpha 7$ nAChR that are analogous to those in the chick $\alpha 7$ nAChR, particularly in critical TM-2 amino acids, would result in similar pharmacological and electrophysiological changes.

SUMMARY OF THE INVENTION

The present invention relates to a variant human $\alpha 7$ subunit in which valine-274 has been changed in analogy with the corresponding chick receptor variant. This variant is analogous to the chick $\alpha 7$ V251T variant with regard to the relative position of the amino acid substitution in the TM-2 region. However, the variant human $\alpha 7$ subunit exhibits unexpectedly different pharmacological and electrophysiological characteristics.

The $\alpha 7$ subunit combines with itself and may combine with other subunits to create various nicotinic acetylcholine receptors. The possibility of combination with yet other proteins, which may or may not be identified as components of other classes of receptor, is not necessarily excluded.

Accordingly, in one embodiment, a DNA molecule is provided, wherein the DNA molecule encodes a variant human $\alpha 7$ subunit in which the valine-274 has been replaced.

In another embodiment, a recombinant vector comprising such a DNA molecule is provided.

In another embodiment, the subject invention is directed to a human $\alpha 7$ subunit variant in which the valine-274 has been replaced.

In still other embodiments, the invention is directed to messenger RNA encoded by the DNA, recombinant host cells transformed or transfected with vectors comprising the DNA or fragments thereof and methods of producing recombinant polypeptides for the treatment of neurodegenerative processes, enzymatic function, affective disorders and immunofunction, using such cells.

5 In another embodiment, compounds such as antagonists are provided, as well as antisense polynucleotides, which are useful in treating conditions such as neurodegenerative processes, enzymatic dysfunction, affective disorders and immunofunction. Methods of 10 treating individuals using these compounds and antisense polynucleotides also are provided.

In yet another embodiment, methods and reagents are provided for detecting the $\alpha 7$ variant.

15 In yet another embodiment, the invention is directed to a method of expressing the human $\alpha 7$ subunit variant in a cell to produce the resultant $\alpha 7$ variant.

In a further embodiment, the invention is directed to a method of identifying compounds that modulate the subunit or receptors containing the subunit and to a method of identifying cytoprotective compounds using such cells.

20 These and other embodiments of the present invention will readily occur to those of ordinary skill in the art in view of the disclosure herein.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 depicts the strategy for generating the human $\alpha 7$ V274T AChR mutant DNA using polymerase chain reaction.

25 Figures 2A-2C show the nucleotide sequence (SEQ ID NO:1) of the human $\alpha 7$ cDNA containing the V274T mutation. The threonine mutation is shown in bold and the restriction sites EcoRV and Kpn1 are shown underlined. Also shown is the deduced amino acid sequence (SEQ ID NO:2) of the human $\alpha 7$ V274T subunit variant derived from the cDNA. The V274T alteration is underlined.

30 Figure 3 graphically compares the concentration-response relationships for ACh (diamonds), (-)-nicotine (circles), GTS-21 (triangles pointing up) and ABT-089 (triangles pointing down) at human $\alpha 7$ V274T nAChR (solid symbols) and human $\alpha 7$ wild-type nAChR (open symbols) expressed in *Xenopus* oocytes.

35 Figure 4 graphically depicts the activation by ACh and decay rate of the human $\alpha 7$ V274T response compared to that of the human $\alpha 7$ WT nAChR.

Figure 5 graphically depicts the responses of human α 7V274T to nAChR antagonists wherein MEC is mecamylamine (10 μ M), MLA is methyllycaconitine (10 nM), and DH β E is dihydro- β -erythroidine (10 μ M). The 0-agonist control was bathing solution without drug and was applied for 20 seconds. The small 0-agonist control responses were measured in each 5 human α 7V274T oocyte and subtracted from agonist responses when data were tabulated.

Figure 6 graphically depicts the current versus voltage relationship of responses to 10 μ M ACh of the human α 7V274T expressed in *Xenopus laevis* oocytes, wherein the circles represent responses measured in modified Barth's solution containing 10 mM Ba²⁺ (90 mM NaCl, 1 mM KCl, 0.66 mM NaNO₃, 10 mM BaCl₂, 2.4 mM NaHCO₃, 2.5 mM sodium 10 pyruvate, and 10 mM Na-HEPES buffer, final pH 7.55) to prevent activation of Ca²⁺-dependent secondary responses (see Briggs *et al.* (1995) *Neuropharmacol.* 34:583-590) and the triangles represent responses measured in "OR2" solution with atropine (82.5 mM NaCl, 2.5 mM KCl, 2.5 mM CaCl₂, 1 mM MgCl₂, 0.5 M atropine, and 5 mM Na-HEPES 15 buffer, final pH 7.4) to replicate the conditions of Galzi *et al.* (1992) *Nature* 359:500-505.

Figure 7 graphically depicts the specific binding of [¹²⁵I] α -Bungarotoxin, an α 7 nAChR-selective ligand, to an HEK-293 clone transfected with variant human α 7V274T.

DETAILED DESCRIPTION OF THE INVENTION

The practice of the present invention will employ, unless otherwise indicated, 20 conventional techniques of molecular biology, microbiology, recombinant DNA technology, electrophysiology, and pharmacology, that are within the skill of the art. Such techniques are explained fully in the literature. See, for example, Sambrook, Fritsch & Maniatis, *Molecular Cloning: A Laboratory Manual*, Second Edition (1989); *DNA Cloning*, Vols. I and II (D.N. Glover ed. 1985); Perbal, B., *A Practical Guide to Molecular Cloning* (1984); the series, 25 *Methods In Enzymology* (S. Colowick and N. Kaplan eds., Academic Press, Inc.); *Transcription and Translation* (Hames *et al.* eds. 1984); *Gene Transfer Vectors For Mammalian Cells* (J. H. Miller *et al.* eds. (1987) Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.); Scopes, *Protein Purification: Principles and Practice* (2nd ed., Springer-Verlag); and *PCR: A Practical Approach* (McPherson *et al.* eds. (1991) IRL Press).

30 All patents, patent applications and publications cited herein, whether *supra* or *infra*, are hereby incorporated by reference in their entirety.

As used in this specification and the appended claims, the singular forms "a," "an" and "the" include plural references unless the content clearly dictates otherwise. Thus, for 35 example, reference to "an amplification primer" includes two or more such primers, reference to "a receptor subunit" includes more than one such subunit, and the like.

A. Definitions

In describing the present invention, the following terms will be employed, and are intended to be defined as indicated below.

The term "AChR" intends a receptor for the neurotransmitter acetylcholine ("ACh").
5 AChRs are broadly subclassified as nicotinic or muscarinic. These types differ in their pharmacology, structures, and signal transduction mechanisms.

The term "nAChR" intends a nicotinic acetylcholine receptor. Although nAChRs of various subunit structures are best known in muscle cells, neurons, and chromaffin cells, they are not necessarily excluded from other cell types (for example, glial cells, mast cells, blood 10 cells, fibroblasts, etc.).

The term "nAChR subunit" intends a proteinaceous molecule which can combine with other such molecules in the formation of a nAChR. For example, the muscle nAChR is believed to be a pentamer comprised of four types of transmembrane subunit: two α 1 subunits, one β 1 subunit, one δ subunit and one γ or ϵ subunit depending upon the nAChR 15 form. Neuronal nAChR analogously are also thought to be pentameric and comprised of related but different subunits. At present, eight neuronal α subunits (α 2- α 9) and three neuronal β subunits (β 2- β 4) have been isolated. Some neuronal nAChR appear to require at least one α subunit and at least one β subunit for a functional complex (i.e., ion channel 20 response to ACh or other agonists). Some subunits, however, may self-assemble to form "homooligomeric" nAChR, as in the case of α 7 nAChR in *Xenopus* oocytes and in transfected mammalian cells. Although the combination of nAChR subunits with subunits related to other types of receptor (for example, other classes of ligand-gated ion channel) has not been demonstrated, it is within the scope of the present invention that such combinations are possible.

25 The term "wild-type" (abbreviated "WT") intends the typical, usual or most common form as it occurs in nature. The human wild-type α 7 nAChR as used herein was described in Doucette-Stamm *et al.* (1993) *Drug Dev. Res.* 30: 252-256. An abbreviation of the form " α 7XnnnO" intends an α 7 subunit in which the amino acid X, located at position nnn relative to the wild-type sequence, has been replaced by amino acid O. Thus, the chick α 7V251T 30 nAChR indicates the chick α 7 nAChR in which the valine located at position 251 in the wild-type receptor has been replaced by a threonine.

A "nicotinic cholinergic agonist" is a compound that binds to and activates a nicotinic acetylcholine receptor. By "activates" is intended the elicitation of one or more pharmacological, physiological, or electrophysiological responses. Such a response includes, but is not limited to, cell membrane depolarization and increased permeability to Ca^{2+} and other cations.
35

A "nicotinic cholinergic antagonist" is a substance that binds to a nicotinic acetylcholine receptor and prevents agonists from activating the receptor. Pure antagonists do not activate the receptor, but some substances may have mixed agonist and antagonist properties. Nicotinic cholinergic channel blockers block the ability of agonists to elicit current flow through the 5 nicotinic acetylcholine receptor channel, but do so by blocking the channel rather than by preventing agonists from binding to and activating the receptor.

A "nicotinic cholinergic modulator" is a substance that influence the activity of the nicotinic acetylcholine receptor through interaction at one or more sites other than the classic agonist binding site. The modulator may itself increase or decrease receptor activity, or may 10 influence agonist activity (for example, potentiating responses) without itself eliciting an overt change in channel current. A single substance can have different properties at different nicotinic acetylcholine receptor subtypes, for example being an agonist at one receptor and antagonist at another, or an antagonist at one and a channel blocker at another.

By "nAChR regulator" is intended a substance that may act as an agonist, antagonist, 15 channel blocker or modulator.

The term "polynucleotide" as used herein means a polymeric form of nucleotides of any length, either ribonucleotides or deoxyribonucleotides. This term refers only to the primary structure of the molecule. Thus, the term includes double- and single-stranded DNA, as well 20 as double- and single-stranded RNA. It also includes modifications, such as by methylation and/or by capping, and unmodified forms of the polynucleotide.

The term "variant" is used to refer to an oligonucleotide sequence which is differs from the related wild-type sequence in one or more nucleotides. Such a variant oligonucleotide is expressed as a protein variant which, as used herein, indicates a polypeptide sequence that 25 differs from the wild-type polypeptide in the substitution, insertion or deletion of one or more amino acids. The variant polypeptide differs in primary structure (amino acid sequence), but may or may not differ significantly in secondary or tertiary structure or in function relative to the wild-type.

The term "mutant" generally refers to an organism or a cell displaying a new genetic character or phenotype as the result of change in its gene or chromosome. In some instances, 30 however, "mutant" may be used in reference to a variant protein or oligonucleotide and "mutation" may refer to the change underlying the variant.

"Polypeptide" and "protein" are used interchangeably herein and indicate a molecular chain of amino acids linked through peptide bonds. The terms do not refer to a specific length of the product. Thus, peptides, oligopeptides, and proteins are included within the definition 35 of polypeptide. The terms include post-translational modifications of the polypeptide, for example, glycosylations, acetylations, phosphorylations and the like. In addition, protein

fragments, analogs, mutated or variant proteins, fusion proteins and the like are included within the meaning of polypeptide.

A "functionally conservative mutation" as used herein intends a change in a polynucleotide encoding a derivative polypeptide in which the activity is not substantially altered compared to that of the polypeptide from which the derivative is made. Such derivatives may have, for example, amino acid insertions, deletions, or substitutions in the relevant molecule that do not substantially affect its properties. For example, the derivative can include conservative amino acid substitutions, such as substitutions which preserve the general charge, hydrophobicity/hydrophilicity, side chain moiety, and/or stearic bulk of the amino acid substituted, for example, Gly/Ala, Val/Ile/Leu, Asp/Glu, Lys/Arg, Asn/Gln, Thr/Ser, and Phe/Trp/Tyr.

By the term "structurally conservative mutant" is intended a polynucleotide containing changes in the nucleic acid sequence but encoding a polypeptide having the same amino acid sequence as the polypeptide encoded by the polynucleotide from which the degenerate variant is derived. This can occur because a specific amino acid may be encoded by more than one "codon," or sequence of three nucleotides, within the polynucleotide.

"Recombinant host cells," "host cells," "cells," "cell lines," "cell cultures," and other such terms denoting microorganisms or higher eukaryotic cell lines cultured as unicellular entities refer to cells which can be, or have been, used as recipients for recombinant vectors or other transfer DNA, immaterial of the method by which the DNA is introduced into the cell or the subsequent disposition of the cell. The terms include the progeny of the original cell which has been transfected. Cells in primary culture as well as cells such as oocytes also can be used as recipients.

A "vector" is a replicon in which another polynucleotide segment is attached, such as to bring about the replication and/or expression of the attached segment. The term includes expression vectors, cloning vectors, and the like.

A "coding sequence" is a polynucleotide sequence that is transcribed into mRNA and/or translated into a polypeptide. The boundaries of the coding sequence are determined by a translation start codon at the 5'-terminus and a translation stop codon at the 3'-terminus. A coding sequence can include, but is not limited to, mRNA, cDNA, and recombinant polynucleotide sequences. Variants or analogs may be prepared by the deletion of a portion of the coding sequence, by insertion of a sequence, and/or by substitution of one or more nucleotides within the sequence. Techniques for modifying nucleotide sequences, such as site-directed mutagenesis, are well known to those skilled in the art. *See, for example, Sambrook et al., supra; DNA Cloning, Vols. I and II, supra; Nucleic Acid Hybridization, supra.*

"Operably linked" refers to a situation wherein the components described are in a relationship permitting them to function in their intended manner. Thus, for example, a control sequence "operably linked" to a coding sequence is ligated in such a manner that expression of the coding sequence is achieved under conditions compatible with the control sequences. A 5 coding sequence may be operably linked to control sequences that direct the transcription of the polynucleotide whereby said polynucleotide is expressed in a host cell.

The term "transfection" refers to the insertion of an exogenous polynucleotide into a host cell, irrespective of the method used for the insertion, or the molecular form of the polynucleotide that is inserted. The insertion of a polynucleotide *per se* and the insertion of a 10 plasmid or vector comprised of the exogenous polynucleotide are included. The exogenous polynucleotide may be directly transcribed and translated by the cell, maintained as a nonintegrated vector, for example, a plasmid, or alternatively, may be stably integrated into the host genome. "Transfection" generally is used in reference to a eukaryotic cell while the term "transformation" is used to refer to the insertion of a polynucleotide into a prokaryotic cell. 15 "Transformation" of a eukaryotic cell also may refer to the formation of a cancerous or tumorigenic state.

The term "isolated," when referring to a polynucleotide or a polypeptide, intends that the indicated molecule is present in the substantial absence of other similar biological macromolecules. The term "isolated" as used herein means that at least 75 wt.%, more 20 preferably at least 85 wt.%, more preferably still at least 95 wt.%, and most preferably at least 98 wt.% of a composition is the isolated polynucleotide or polypeptide. An "isolated polynucleotide" that encodes a particular polypeptide refers to a polynucleotide that is substantially free of other nucleic acid molecules that do not encode the subject polypeptide; however, the molecule may include functionally and/or structurally conservative mutations as 25 defined herein.

The following single-letter amino acid abbreviations are used throughout the text:

	Alanine	A	Arginine	R
	Asparagine	N	Aspartic acid	D
	Cysteine	C	Glutamine	Q
30	Glutamic acid	E	Glycine	G
	Histidine	H	Isoleucine	I
	Leucine	L	Lysine	K
	Methionine	M	Phenylalanine	F
	Proline	P	Serine	S
35	Threonine	T	Tryptophan	W
	Tyrosine	Y	Valine	V

B. General Methods

A variant human $\alpha 7$ subunit, a polynucleotide encoding the variant subunit, and methods of making the variant subunit are provided herein. The invention includes not only the variant subunit but also methods for screening compounds using the variant subunit, cells expressing the variant subunit.

In one preferred embodiment, the polynucleotide encodes a human $\alpha 7$ subunit variant in which the valine-274 of the wild-type $\alpha 7$ subunit has been replaced. Preferably, the polynucleotide encodes a human $\alpha 7$ subunit in which the valine-274 has been replaced by a threonine, or a conservative substitution for the threonine, for example, serine.

The human $\alpha 7$ variant nAChR exhibits both similar and unexpectedly different properties relative to other structurally related nAChRs. For example, as with the chick $\alpha 7$ V251T variant, the human $\alpha 7$ V274T, responses to cholinergic agonists decay slowly compared to the human wild-type $\alpha 7$ nAChR responses. In addition, human $\alpha 7$ V274T is about two orders of magnitude more sensitive to cholinergic receptor agonists such as nicotine and ACh compared to the wild-type.

The human and chick receptor variants differ pharmacologically, for example, in that human $\alpha 7$ V274T is weakly activated by dihydro- β -erythroidene (DH β E) while chick $\alpha 7$ V251T is strongly activated (Figure 5 and Galzi *et al.* (1992). Mutations in the channel 20 domain of a neuronal nicotinic receptor convert ion selectivity from cationic to anionic. *Nature* 359: 500-505). In addition, *d*-tubocurarine is a potent antagonist of human $\alpha 7$ V274T compared to an activator of the related chick $\alpha 7$ L247T mutant (Bertrand *et al.* (1992) Unconventional pharmacology of a neuronal nicotinic receptor mutated in the channel domain. *Proc. Natl. Acad. Sci. (U.S.A.)* 89: 1261-1265). The human and chick $\alpha 7$ receptor variants 25 are electrophysiologically different as well. For example, the chick $\alpha 7$ V251T nAChR does not exhibit inward current rectification (Galzi *et al.* (1992), unlike both chick and human $\alpha 7$ wild-type nAChR which exhibit strong inward rectification (Galzi *et al.* (1992), *supra*, and Briggs *et al.* (1995) *Neuropharmacol.* 34: 583-590). The human $\alpha 7$ V274T nAChR, in contrast to the chick $\alpha 7$ V251T nAChR, rectifies above 0 mV similarly to the wild-type receptor (Figure 6).

30 DNA encoding the human variant $\alpha 7$ nAChR subunit can be derived from genomic or cDNA, prepared by synthesis, or by a combination of techniques. The DNA can then be used to express the human variant $\alpha 7$ nAChR subunit or as a template for the preparation of RNA using methods well known in the art (*see, Sambrook et al., supra*)

35 One method for obtaining the desired DNA involves isolating cDNA encoding the wild-type human $\alpha 7$ nAChR subunit as described by Doucette-Stamm *et al.* (1993), *supra*. The wild-type cDNA thus obtained is then modified and amplified using the polymerase chain

reaction ("PCR") and mutated primer sequences to obtain the DNA encoding the human variant $\alpha 7$ nAChR subunit. More particularly, PCR employs short oligonucleotide primers (generally 10-20 nucleotides in length) that match opposite ends of a desired sequence within the wild-type DNA molecule. The sequence between the primers need not be known. The initial 5 template can be either RNA or DNA. If RNA is used, it is first reverse transcribed to cDNA. The cDNA is then denatured, using well known techniques such as heat, and appropriate oligonucleotide primers are added in molar excess.

Primers bearing the mutation will hybridize to the wild-type polynucleotide at a temperature slightly below that of the wild-type primer-polynucleotide duplex. The primer can 10 be made specific by keeping primer length and base composition within relatively narrow limits, and by keeping the mutant base or bases centrally located (Zoller *et al.* (1983) *Meth. Enzymol.* 100:468). Primer extension is effected using DNA polymerase in the presence of deoxynucleotide triphosphates or nucleotide analogs. The resulting product includes the 15 respective primers at their 5'-termini, covalently linked to the newly synthesized complements of the original strands. The replicated molecule is again denatured, hybridized with primers, and so on, until the product is sufficiently amplified. Such PCR methods are described in for example, U.S. Patent Nos. 4,965,188; 4,800,159; 4,683,202; 4,683,195; incorporated herein by reference in their entireties. The product of the PCR is cloned and the clones containing the mutated DNA, derived by segregation of the primer extended strand, selected. Selection can be 20 accomplished using the mutant primer as a hybridization probe.

Alternatively, the wild-type DNA may be obtained from an appropriate DNA library. DNA libraries may be probed using the procedure described by Grunstein *et al.* (1975) *Proc. Natl. Acad. Sci. USA* 73:3961.

Alternatively still, the $\alpha 7V274T$ variant could be generated using an RT-PCR (reverse 25 transcriptase-polymerase chain reaction) approach starting with human RNA. For example, single-stranded cDNA is synthesized from human RNA (approx. 1.5 g) as the template using standard reverse transcriptase procedures. Next, the cDNA is amplified in two segments and the mutation is introduced using PCR and two pairs of primers. The internal primers are designed to carry the codon for threonine (T) or other desired change in place of the wild-type 30 valine (V) at position 274 (see also Example 1 p. 28 and Figure 1). The products of the two PCR reactions are combined using the 3' and 5' end primers to re-amplify the full length coding sequence of $\alpha 7V274T$. This is but one example of the generation of $\alpha 7V274T$ from a human brain template.

Synthetic oligonucleotides may be prepared using an automated oligonucleotide 35 synthesizer such as that described by Warner (1984) *DNA* 3:401. If desired, the synthetic strands may be labelled with ^{32}P by treatment with polynucleotide kinase in the presence of

³²P-ATP, using standard conditions for the reaction. DNA sequences including those isolated from genomic or cDNA libraries, may be modified by known methods which include site-directed mutagenesis as described by Zoller (1982) *Nucleic Acids Res.* 10:6487. Briefly, the DNA to be modified is packaged into phage as a single stranded sequence, and converted to a double stranded DNA with DNA polymerase using, as a primer, a synthetic oligonucleotide complementary to the portion of the DNA to be modified, and having the desired modification included in its own sequence. Culture of the transformed bacteria, which contain replications of each strand of the phage, are plated in agar to obtain plaques. Theoretically, 50% of the new plaques contain phage having the mutated sequence, and the remaining 50% have the original sequence. Replicates of the plaques are hybridized to labelled synthetic probe at temperatures and conditions suitable for hybridization with the correct strand, but not with the unmodified sequence. The sequences which have been identified by hybridization are recovered and cloned. Alternatively, it may be necessary to identify clones by sequence analysis if there is difficulty in distinguishing the small difference variant from wild-type by hybridization. In any case, the DNA would be sequence-confirmed.

Once produced, the DNA may then be incorporated into a cloning vector or an expression vector for replication in a suitable host cell. Vector construction employs methods known in the art. Generally, site-specific DNA cleavage is performed by treating with suitable restriction enzymes under conditions which generally are specified by the manufacturer of these commercially available enzymes. After incubation with the restriction enzyme, protein is removed by extraction and the DNA recovered by precipitation. The cleaved fragments may be separated using, for example, polyacrylamide or agarose gel electrophoresis methods, according to methods known by those of skill in the art.

Sticky end cleavage fragments may be blunt ended using *E. coli* DNA polymerase I (Klenow) in the presence of the appropriate deoxynucleotide triphosphates (dNTPs) present in the mixture. Treatment with S1 nuclease also may be used, resulting in the hydrolysis of any single stranded DNA portions.

Ligations are performed using standard buffer and temperature conditions using T4 DNA ligase and ATP. Alternatively, restriction enzyme digestion of unwanted fragments can be used to prevent ligation.

Standard vector constructions generally include specific antibiotic resistance elements. Ligation mixtures are transformed into a suitable host, and successful transformants selected by antibiotic resistance or other markers. Plasmids from the transformants can then be prepared according to methods known to those in the art usually following a chloramphenicol amplification as reported by Clewell *et al.* (1972) *J. Bacteriol.* 110:667 may be added. The DNA is isolated and analyzed usually by restriction enzyme analysis and/or sequencing.

Sequencing may be by the well-known dideoxy method of Sanger *et al.* (1977) *Proc. Natl. Acad. Sci. USA* 74:5463) as further described by Messing *et al.* (1981) *Nucleic Acid Res.* 9:309, or by the method reported by Maxam *et al.* (1980) *Meth. Enzymol.* 65:499. Problems with band compression, which are sometimes observed in GC rich regions, are overcome by 5 use of, for example, T-deazoguanosine or inosine, according to the method reported by Barr *et al.* (1986) *Biotechniques* 4:428.

Host cells are genetically engineered with the vectors of this invention which may be a cloning vector or an expression vector. The vector may be in the form of a plasmid, a viral 10 particle, a phage, etc. The engineered host cells can be cultured in conventional nutrient media modified as appropriate for activating promoters, selecting transformants/transfectants or amplifying the subunit-encoding polynucleotide. The culture conditions, such as temperature, pH and the like, generally are similar to those previously used with the host cell selected for expression, and will be apparent to those of skill in the art.

Both prokaryotic and eukaryotic host cells may be used for expression of desired 15 coding sequences when appropriate control sequences that are compatible with the designated host are used. For example, among prokaryotic hosts, *Escherichia coli* is frequently used. Also, for example, expression control sequences for prokaryotes include but are not limited to promoters, optionally containing operator portions, and ribosome binding sites. Transfer vectors compatible with prokaryotic hosts can be derived from, for example, the plasmid 20 pBR322 that contains operons conferring ampicillin and tetracycline resistance, and the various pUC vectors, that also contain sequences conferring antibiotic resistance markers. These markers may be used to obtain successful transformants by selection. Commonly used prokaryotic control sequences include but are not limited to the lactose operon system (Chang *et al.* (1977) *Nature* 198:1056), the tryptophan operon system (reported by Goeddel *et al.* 25 (1980) *Nucleic Acid Res.* 8:4057) and the lambda-derived P1 promoter and N gene ribosome binding site (Shimatake *et al.* (1981) *Nature* 292:128) and the hybrid *Tac* promoter (De Boer *et al.* (1983) *Proc. Natl. Acad. Sci. USA* 292:128) derived from sequences of the *trp* and *lac* UV5 promoters. The foregoing systems are particularly compatible with *E. coli*; however, other prokaryotic hosts such as strains of *Bacillus* or *Pseudomonas* may be used if desired.

Eukaryotic hosts include yeast and mammalian cells in culture systems. *Pichia* 30 *pastoris*, *Saccharomyces cerevisiae* and *S. carlsbergensis* are commonly used yeast hosts. Yeast-compatible vectors carry markers that permit selection of successful transformants by conferring protrophy to auxotrophic mutants or resistance to heavy metals on wild-type strains. Yeast compatible vectors may employ the 2- μ origin of replication (Broach *et al.* (1983) *Meth. Enzymol.* 101:307), the combination of CEN3 and ARS1 or other means for assuring replication, such as sequences that will result in incorporation of an appropriate fragment into 35

the host cell genome. Control sequences for yeast vectors are known in the art and include but are not limited to promoters for the synthesis of glycolytic enzymes, including the promoter for 3-phosphoglycerate kinase. See, for example, Hess *et al.* (1968) *J. Adv. Enzyme Reg.* 7:149, Holland *et al.* (1978) *Biochemistry* 17:4900 and Hitzeman (1980) *J. Biol. Chem.* 255:2073.

5 For example, some useful control systems are those that comprise the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) promoter or alcohol dehydrogenase (ADH) regulatable promoter, terminators also derived from GAPDH, and, if secretion is desired, leader sequences from yeast alpha factor. In addition, the transcriptional regulatory region and the transcriptional initiation region which are operably linked may be such that they are not
10 naturally associated in the wild-type organism.

Mammalian cell lines available as hosts for expression are known in the art and are available from depositories such as the American Type Culture Collection. These include but are not limited to HeLa cells, human embryonic kidney (HEK) cells, Chinese hamster ovary (CHO) cells, baby hamster kidney (BHK) cells, and others. Suitable promoters for
15 mammalian cells also are known in the art and include viral promoters such as that from Simian Virus 40 (SV40), Rous sarcoma virus (RSV), adenovirus (ADV), bovine papilloma virus (BPV), cytomegalovirus (CMV). Mammalian cells also may require terminator sequences and poly A addition sequences; enhancer sequences which increase expression also may be included, and sequences which cause amplification of the gene also may be desirable. These
20 sequences are known in the art. Vectors suitable for replication in mammalian cells may include viral replicons, or sequences which ensure integration of the appropriate sequences encoding the variant $\alpha 7$ nAChR subunit into the host genome. An example of a mammalian expression system for nAChRs is described in Gopalakrishnan *et al.* (1995) Stable expression and pharmacological properties of the human $\alpha 7$ nicotinic acetylcholine receptor. *Eur. J.*
25 *Pharmacol.-Mol. Pharmacol.* 290: 237-246.

Other eukaryotic systems are also known, as are methods for introducing polynucleotides into such systems, such as amphibian cells using methods described in Briggs *et al.* (1995) *Neuropharmacol.* 34:583-590, insect cells using methods described in Summers and Smith, *Texas Agricultural Experiment Station Bulletin No. 1555* (1987), and the like.

30 The baculovirus expression system can be used to generate high levels of recombinant proteins in insect host cells. This system allows for high level of protein expression, while post-translationally processing the protein in a manner similar to mammalian cells. These expression systems use viral promoters that are activated following baculovirus infection to drive expression of cloned genes in the insect cells (O'Reilly *et al.* (1992), *Baculovirus Expression Vectors: A Laboratory Manual*, IRL/Oxford University Press).

Transfection may be by any known method for introducing polynucleotides into a host cell, including packaging the polynucleotide in a virus and transducing a host cell with the virus, by direct uptake of the polynucleotide by the host cell, and the like, which methods are known to those skilled in the art. The transfection procedures selected depend upon the host to be transfected and are determined by the rountineer.

The expression of the variant receptor subunit may be detected by use of a radioligand selective for the receptor. For example, for the nicotinic cholinergic receptor, such a ligand may be [¹²⁵I]α-bungarotoxin. However, any radioligand binding technique known in the art may be used to detect the receptor subunit (see, for example, Winzor *et al.* (1995) *Quantitative Characterization of Ligand Binding*, Wiley-Liss, Inc., NY).

The variant nAChR polypeptide is recovered and purified from recombinant host cell cultures expressing the same by known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, hydroxyapatite chromatography or lectin chromatography. Protein refolding steps can be used, as necessary, in completing configuration of the protein. Finally, high performance liquid chromatography (HPLC) can be employed for final purification steps.

The human α7 variant polypeptide, or fragments thereof, of the present invention may also be synthesized by conventional techniques known in the art, for example, by chemical synthesis such as solid phase peptide synthesis. In general, these methods employ either solid or solution phase synthesis methods. See, for example, J. M. Stewart and J. D. Young, *Solid Phase Peptide Synthesis*, 2nd Ed., Pierce Chemical Co., Rockford, IL (1984) and G. Barany and R. B. Merrifield, *The Peptides: Analysis, Synthesis, Biology*, editors E. Gross and J. Meienhofer, Vol. 2, Academic Press, New York, (1980), pp. 3-254, for solid phase peptide synthesis techniques; and M. Bodansky, *Principles of Peptide Synthesis*, Springer-Verlag, Berlin (1984) and E. Gross and J. Meienhofer, Eds., *The Peptides: Analysis, Synthesis, Biology, supra*, Vol. 1, for classical solution synthesis.

In one preferred system, either the DNA or the RNA derived therefrom, both of which encode the desired variant human α7 nAChR subunit, may be expressed by direct injection into a cell, such as a *Xenopus laevis* oocyte. Using this method, the functionality of the human α7 nAChR subunit variant encoded by the DNA or the mRNA can be evaluated as follows (see Dascal (1987) *CRC Crit. Rev. Biochem.* 22:317-387). A variant-encoding polynucleotide is injected into an oocyte for translation into a functional receptor subunit. The function of the expressed variant human α7 nAChR can be assessed in the oocyte by a variety of electrophysiological techniques including intracellular voltage recording, two-electrode voltage clamp, patch clamp methods, and the like. The cation-conducting channel intrinsic to the

nAChR opens in response to ACh or other nicotinic cholinergic agonists, permitting the flow of transmembrane current. This current can be monitored directly by voltage clamp techniques or indirectly by intracellular voltage recording, wherein changes in membrane potential due to the induced current are measured.

5 Receptors expressed in a recombinant host cell may be used to identify compounds that modulate nAChR activity. In this regard, the specificity of the binding of a compound showing affinity for the receptor is demonstrated by measuring the affinity of the compound for cells expressing the receptor or membranes from these cells. This may be done by measuring specific binding of labeled (for example, radioactive) compound to the cells, cell 10 membranes or isolated receptor, or by measuring the ability of the compound to displace the specific binding of a standard labeled ligand. Expression of variant receptors and screening for compounds that bind to, or inhibits the binding of labeled ligand to these cells or membranes provides a method for rapid selection of compounds with high affinity for the receptor. These compounds may be agonists or antagonists for the receptor.

15 Expressed receptors may also be used to screen for compounds that modulate nicotinic acetylcholine receptor activity, i.e., nicotinic cholinergic agonists or antagonists. One method for identifying compounds that modulate nAChR activity, comprises providing a cell that expresses a variant human $\alpha 7$ nicotinic acetylcholine receptor (nAChR) polypeptide having an amino acid substitution at position valine-274 of the wild-type human $\alpha 7$ nAChR polypeptide, 20 combining a test compound with the cell and measuring the effect of the test compound on the variant receptor activity. The cell may be a bacterial cell, a mammalian cell, a yeast cell, an amphibian cell or any other cell expressing the receptor. Preferably, the cell is a mammalian cell or an amphibian cell. Thus, for example, a test compound is evaluated for its ability to elicit an appropriate response, for example, the stimulation of transmembrane current flow, or 25 for its ability to inhibit the response to a cholinergic agonist.

30 In addition, expressed receptors may be used to screen compounds that exhibit a cytoprotective effect. Abnormal activation of membrane channels is a potential cause of neurodegenerative disease. In this regard, a number of inherited human disorders are accompanied by neuronal degeneration (Adams *et al.* (1989) *Degenerative Disease of the Nervous System*, in *Principles of Neurology*, McGraw-Hill, NY, pp. 921-967). Many model systems have been used to study the causes of these diseases. For example, mutations in proteins that have extensive sequence similarity to proteins that contribute to the amiloride-sensitive sodium ion channel have been associated with vacuolated neurodegeneration in the nematode *C. elegans* (Canessa *et al.* (1993) *Nature*, 361:467-470; Canessa *et al.* (1994) *Nature*, 367:463-467; Lingueglia *et al.* (1993) *FEBS Lett.* 318:95-99; and Voilley *et al.* (1994) *Proc. Natl. Acad. Sci. USA* 91:247-251). A so-called "gain-of-function" mutation in the *deg-3* 35

protein of *C. elegans*, causes vacuolated degeneration of a small set of neurons (Treinin *et al.* (1995), *supra*). Studies of this mutation suggested to these investigators that mutation in neuronal acetylcholine receptors may lead to death of specific neuronal populations.

5 Additionally, the $\alpha 7$ variant can be used to screen for compounds useful in treating disorders such as alterations in sensory gating, immunofunction and neuropathic pain, for example, pain associated with cancerous conditions, post herpetic neuralgia, diabetic neuropathy and osteoarthritis. Further, the $\alpha 7$ variant could be used to treat or to kill cancerous cells.

10 Accordingly, nicotinic drugs are considered potential therapeutic agents in several neurodegenerative disorders including, without limitation, Alzheimer's disease, Down's syndrome, kuru, Parkinson's disease, multiple system atrophy, neuropathic pain and the like, in which they may be useful in slowing cell death. Activation of the wild type $\alpha 7$ nAChR appears to elicit cytoprotective properties (for example, reduced cell lysis, see Donnelly-
15 Roberts *et al.* (1996) *In vitro* neuroprotective properties of the novel cholinergic channel activator (ChCA), ABT-418. *Brain Res.* 719: 36-44). However, it is not yet finally established whether a full agonist or partial agonist is preferable, nor, if the latter, what type of partial agonist is best (for example, one that stabilizes the open and desensitized states or one that stabilizes the open and resting states of the receptor). This variant $\alpha 7$ nAChR can be used to evaluate these questions, and to select among ligands for specific types of partial agonists or specific types of antagonists. That is because this variant $\alpha 7$ nAChR conducts current in the desensitized as well as the open states, unlike the wild type receptor that conducts only in the open state (see Bertrand and Changeux (1995) Nicotinic receptor: An allosteric protein specialized for intercellular communication. *Sem.Neurosci.* 7: 75-90). Thus, with the human variant nAChR subunit agonist potency is shifted two orders of magnitude to a level consistent with agonist affinity for the desensitized state. Furthermore, ligands that are partial agonists at the wild type $\alpha 7$ nAChR subunit because of their ability to stabilize desensitized as well as open states would be expected to have increased efficacy at the variant nAChR subunit due to its ability to conduct in the desensitized state. Examples of such potency and efficacy shifts are shown for the human $\alpha 7$ V274T nAChR in Figure 3.

20 30 Thus, $\alpha 7$ nAChR ligand pharmacology can be defined in novel ways through the use of the human variant nAChR subunit. Substances could be antagonists at the wild type $\alpha 7$ nAChR due to their ability to stabilize the non-conducting desensitized state, or due to other mechanisms such as stabilizing the resting state or blocking the ion channel. Similar mechanisms could contribute to partial agonism at the wild type $\alpha 7$ nAChR. The ability of a ligand to stabilize the desensitized state could be evaluated by comparing the ligand's potency and efficacy at the variant $\alpha 7$ nAChR (for example, human $\alpha 7$ V274T) to its potency and

efficacy at the wild-type $\alpha 7$ nAChR. The interaction of compounds with the nAChR can be identified using several methods, including, but not limited to, electrophysiologic measurement of transmembrane current flow or electrical potential, measurement of the fluorescence of potential- or ion-sensitive dyes, or measurement of radioactive ion flux (for example $^{22}\text{Na}^+$ or $^{86}\text{Rb}^+$) and a variety of $\alpha 7$ nAChR expression systems, for example transfected mammalian cells in culture or injected amphibian cells. This novel definition of $\alpha 7$ nAChR pharmacology coupled with measures of $\alpha 7$ ligand effect on cell or animal functioning could be critical to the development of novel therapeutics. For example, it could be determined whether a ligand that stabilizes the desensitized state of the $\alpha 7$ nAChR subunit (partial agonist or antagonist) is preferable for cytoprotection. Likewise, the type of ligand more or less useful in other nicotinic applications, such as cognition, memory, anxiety, attention, sensory gating (psychoses and schizophrenia), etc. could be evaluated using variant $\alpha 7$ nAChR subunits alone or in combination with other receptor subunits.

In addition to screening test compounds, the expressed variant $\alpha 7$ subunit may be used to investigate mechanisms of cytotoxicity and cytoprotection. The evidence that activation of $\alpha 7$ nAChR is cytoprotective comes from the finding that nAChR agonists elicit cytoprotection in cells expressing the $\alpha 7$ nAChR subunit and that this cytoprotection is inhibited by selective $\alpha 7$ antagonists (for example see Donnelly-Roberts *et al.*, *supra*). The mechanism is unknown but may involve the stimulation of Ca^{2+} influx. If so, then the increased Ca^{2+} influx mediated by the variant $\alpha 7$ nAChR, due to maintained Ca^{2+} permeability with prolonged current activation, may augment the cytoprotection. On the other hand, as excessive intracellular Ca^{2+} is known to be cytotoxic, excessive expression or stimulation of the variant $\alpha 7$ nAChR could cause cell death, perhaps as observed in *C. elegans* carrying the endogenous mutation in *deg3* analogous to the $\alpha 7$ variant. Alternatively still, the $\alpha 7$ nAChR subunit may also function through mechanisms dependent upon a change in receptor state (for example, from resting to desensitized conformation), which may influence its interaction with other proteins, but not necessarily dependent upon a change in ion flux or electrical potential. The variant $\alpha 7$ nAChR subunit would be critical in determining such mechanisms as it would allow one to identify ligands that favor different receptor states, and as it provides a tool for manipulating nAChR channel current independently from nAChR conformation and ligand binding.

Cytoprotective or cytotoxic compounds that interact with the variant nAChR may be identified using several methods. One such method comprises providing a cell that expresses a variant human $\alpha 7$ nAChR subunit having an amino acid substitution at position valine-274 of the wild-type human $\alpha 7$ nAChR polypeptide, combining a test compound with the cell, and monitoring the cell for an indicator of cytotoxicity. If it is necessary to control spontaneous action of the variant nAChR subunit, it may be stably expressed in a recombinant mammalian

cell line under the control of an inducible promoter, for example, the LacSwitch system which is inducible by isopropylthiogalactoside ("IPTG"). Expression of the variant $\alpha 7$ nAChR subunit would be maintained at a low level until induction by the addition of IPTG.

Alternatively, with or without an inducible promoter, the transfected cells could be cultured in the presence of an $\alpha 7$ nAChR blocker, such as methyllycaconitine ("MLA") or mecamylamine, that would prevent or reduce cytotoxic action. Both blockers are reversible, permitting one to measure the effect of test compound on $\alpha 7$ nAChR function after the blocker is washed out.

Cytoprotective compounds can be identified by their ability to reduce cell death while cytotoxic compounds can be identified by their ability to promote cell death. That these effects are mediated by the $\alpha 7$ nAChR subunit, variant or wild type, can be identified by the ability of an $\alpha 7$ nAChR blocker to prevent the effect. Cell death, or cytotoxicity, can be monitored by a variety of techniques including but not limited to measurement of cell number or density in the culture, of cell growth rate (for example incorporation of labeled nucleotide or amino acid), or of cell integrity for example by uptake of a dye (for example trypan blue is excluded by healthy cells) or by the release of a cytoplasmic constituent such as lactate dehydrogenase (LDH).

Cytoprotective agents may also be screened for their ability to antagonize a variant nAChR to a greater extent than a wild-type nAChR, or for their ability to augment the decay rate of variant nAChR compared to the wild-type nAChR, using methods described in the examples provided below.

In addition, the DNA, or RNA derived therefrom, can be used to design oligonucleotide probes for nAChR DNAs that express variant subunits. As used herein, the term "probe" refers to a structure comprised of a polynucleotide, as defined above, which contains a nucleic acid sequence complementary to a nucleic acid sequence present in a target polynucleotide. The polynucleotide regions of probes may be composed of DNA, and/or RNA, and/or synthetic nucleotide analogs. Such probes could be useful in *in vitro* hybridization assays to distinguish $\alpha 7$ variant from wild-type message, with the proviso that it may be difficult to design a method capable of making such a distinction given the small difference in coding between variant and wild-type. Alternatively, a PCR-based assay could be used to amplify the sample RNA or DNA for sequence analysis.

Furthermore, the variant nAChR subunit can be used to prepare polyclonal or monoclonal antibodies using techniques that are well known in the art. The variant nAChR subunit or relevant fragments can be obtained using the recombinant technology outlined below, i.e., a recombinant cell that expresses the subunit or fragments can be cultured to produce quantities of the subunit or fragment that can be recovered and isolated. Alternatively, the variant nAChR subunit or fragment thereof can be synthesized using conventional polypeptide synthetic techniques as provided below. Monoclonal antibodies that display

specificity and selectivity for the variant nAChR subunit can be labeled with a measurable and detectable moiety, for example, a fluorescent moiety, radiolabels, enzymes, chemiluminescent labels and the like, and used in *in vitro*, or *in situ* immunofluorescent assays, or the like. The antibodies can be used to identify variant nAChR subunit for immunodiagnostic purposes.

5 Below are examples of specific embodiments for carrying out the present invention. The examples are offered for illustrative purposes only, and are not intended to limit the scope of the present invention in any way. In preparing the examples, efforts have been made to ensure accuracy with respect to numbers used (for example, amounts, temperatures, etc.), but some experimental error and deviation should, of course, be allowed for.

10

Materials

Acetylcholine chloride ("ACh"), collagenase Type 1A, *d*-tubocurarine chloride ("dTc"), gentamicin and mecamylamine hydrochloride ("MEC"), were obtained from Sigma Chemical Company (St. Louis, Missouri, U.S.A.). Dihydro- β -erythroidine hydrobromide ("DHBE"), and methyllycaconitine citrate ("MLA") were obtained from Research Biochemicals International (Natick, Massachusetts, U.S.A.). Tricaine (3-aminobenzoic acid ethyl ester methanesulfonate; Finquel) was obtained from Argent Chemical Laboratories (Fisheries Chemical Division, Redmond, Washington, U.S.A.).

20 Preparation of Human α 7 Wild-Type cDNA

The human α 7 nAChR subunit cDNA reported by Doucette-Stamm *et al.* (1993), *supra*, was modified to include the complete human signal peptide (MRCSPGGVWLALAASLLHVSLQGEF (SEQ ID NO:3)) reported by Elliott *et al.* (1993) *Soc. Neurosci. Abstr.* 19:69. The following oligonucleotide was synthesized:

25 5'-GGGGCAGCACTCGAGCCAT**G**AGGTGTAGCCCCGGAGGAGTGTGGCTGGCA
CTGGCAGCAT**T**CTCCTGCACGTGTCCCTGCAAGGCGAG**T**CCAGAGGAAG**C**TTA
CAAGGAGGGG-3' (SEQ ID NO:4). This oligonucleotide contains an *Xho* I restriction site (italics) and an ATG initiation codon (bold) followed by the next 28 codons of the human α 7 nAChR subunit cDNA sequence. It encodes the complete signal peptide and extends to the Hind III site (underlined) present in the α 7 nAChR subunit cDNA. The *Xho* I and Hind III sites were flanked with additional nucleotides to make them internal within the molecule. Additionally, the reverse complement of this oligonucleotide was synthesized. The oligonucleotides were annealed together, digested with *Xho* I and Hind III, and then ligated into a pBluescript vector containing the human α 7 subunit cDNA previously digested with *Xho* I and Hind III. This created a new cDNA encoding a full length human α 7 nAChR subunit. The sequence of the new cDNA was confirmed by dideoxy sequencing. The cDNA

was excised from pBluescript with Xho I and Not I, the 5' overhangs were filled-in with Klenow polymerase, linked with Bst XI adapters, digested with Bst XI, and ligated into the Bst XI site of the pRcCMV vector (Invitrogen). The orientation of the insert in the expression vector was determined by restriction analysis with enzymes cutting the $\alpha 7$ nAChR subunit cDNA at asymmetrical positions.

Expression of $\alpha 7$ nAChR in *Xenopus laevis* Oocytes and Measurement of Functional Characteristics

The preparation of *Xenopus laevis* oocytes, injection with receptor RNA or DNA, and measurement of $\alpha 7$ nAChR responses using two-electrode voltage-clamp followed procedures described previously for the wild-type human $\alpha 7$ nAChR (Briggs *et al.* (1995), *supra*) except that atropine was not routinely present in the bathing solution. Oocytes were maintained at 17-18°C in normal Barth's solution (90 mM NaCl, 1 mM KCl, 0.66 mM NaNO₃, 0.74 mM CaCl₂, 0.82 mM MgCl₂, 2.4 mM NaHCO₃, 2.5 mM sodium pyruvate, and 10 mM Na 15 N-(2-hydroxyethyl)piperazine-N'-(2-ethanesulfonic acid) ("HEPES") buffer, final pH 7.55) containing 100 g/ml gentamicin. Responses were measured at a holding potential of -60 mV in modified Barth's solution containing 10 mM BaCl₂ and lacking CaCl₂ and MgCl₂. However, in some experiments (Figure 6) the cell potential was intentionally varied in order to determine the response current-voltage relationship and OR2 plus atropine (82.5 mM NaCl, 20 2.5 mM KCl, 2.5 mM CaCl₂, 1 mM MgCl₂, 5 mM Na-HEPES (pH 7.4) and 0.5 M atropine sulfate) was used to replicate conditions used by Galzi *et al.* (1992), *supra*, to study chick $\alpha 7$ nAChR. Agonist was applied briefly using a computer-controlled solenoid valve and a push/pull applicator positioned to within 200-400 m from the oocyte. Responses were recorded by computer in synchrony with agonist application. Antagonists were included with 25 agonist in the push/pull applicator and were applied to the bath by superfusion for at least 3 minutes before application of agonist. Responses were quantified by measuring the peak amplitude.

Human $\alpha 7V274T$ responses, unlike human $\alpha 7WT$ responses, tended to increase significantly during the experiments. Therefore, experimental trials were bracketed, before and 30 after, by control applications of 10 M ACh in the same oocyte. All responses were normalized to the 10 M ACh responses in order to account for changes in sensitivity within the experiment and for variability in receptor expression among oocytes.

Example 1
Preparation of Human α 7V274T cDNA

To generate the variant α 7V274T in an expression vector, the wild-type α 7 nAChR 5 subunit gene was digested with EcoR V and Kpn I restriction enzymes and the digested segment was replaced with a mutant PCR product by ligation using the procedures described below.

The strategy, diagrammed in Figure 1, used two PCR steps followed by digesting with 10 restriction enzymes to produce a mutated fragment of the wild-type α 7 nAChR subunit cDNA and subcloning the mutated fragment into the wild-type human α 7 cDNA. In the first step (A), two DNA fragments carrying the desired mutation were generated by PCR using appropriate 15 primers. The mutated nucleotide was incorporated in the reverse primer (X-3') for the longer fragment and in the forward primer (Y-5') for the shorter fragment. The two external primers (X-5' and Y-3') were chosen so that the final PCR product would contain EcoRV and KpnI restriction sites.

The longer 5' fragment was generated using the forward external primer 5'-GTTTGGGTCCCTGGTCTTACG-3' (SEQ ID NO:5) and the reverse internal primer 5'-GCAGCATGAAGGTGGTAAGAGAG-3' (SEQ ID NO:6) bearing the mutation. The shorter 3' fragment was generated using the forward internal primer 20 5'-CTCTCTTACCAACCTTCATGCTGC-3' (SEQ ID NO:7), also bearing the mutation, and the reverse external primer 5'-GTACTGCAGCACGATCACCG-3' (SEQ ID NO:8). The conditions for PCR consisted of 100 ng input α 7 DNA, 2X Pfu buffer, 100 ng of each primer pair and 0.625 U Pfu enzyme (Stratagene, La Jolla, CA). Reactions were carried out in a Perkin-Elmer 9600 for 20 cycles at 95°C for 24 seconds, 60°C for 22 seconds then 72°C for 78 25 seconds.

In the second PCR step (B), these two fragments were reassembled using the external primers. The sequence was reamplified and a longer DNA fragment bearing the desired mutation was generated.

In the next step (C), the product of step (B) was digested with KpnI and EcoRV, 30 gel-purified, and ligated into the wild-type human α 7 cDNA previously digested with KpnI and EcoRV. Dideoxy sequencing of the final cDNA showed the presence of the desired mutation and that no other mutation had been introduced during the PCR process.

Figures 2A-2C shows the nucleotide sequence (SEQ ID NO:1) of the human α 7V274T 35 cDNA mutant. The amino acid sequence of the human α 7V274T variant (SEQ ID NO:2) is also shown in Figures 2A-2C.

Example 2
Concentration-Response Relationships
for Agonists in Human α 7V274T and Wild-Type nAChR

5 Responses to various agonist concentrations were measured using human α 7V274T nAChR subunits expressed from the DNA prepared in Example 1 that was injected into *Xenopus laevis* oocytes as described above. The responses were measured at peak amplitude and were normalized to the response to 10 μ M ACh. Data points (Figure 3) show the mean \pm s.e.m. of the normalized responses (n=4 to 10 for ACh, n=3 to 4 for (-)-nicotine n=3 to 5 for 10 GTS-21, and n=2 to 5 for ABT-089). The curves depicted in Figure 3 show the Hill equation fitted to the data (SigmaPlot software, Jandel Scientific, San Rafael, California, U.S.A.) with the exception of the small responses to GTS-21 and ABT-089 at the α 7 wild-type. At the 15 human α 7 wild type nAChR, ACh and (-)-nicotine had EC₅₀ values of 156 \pm 20 μ M and 83 \pm 10 μ M, respectively, and with Hill coefficients of 0.94 \pm 0.09 and 1.2 \pm 0.2, respectively. GTS-21 and ABT-089 were partial agonists whose EC₅₀ values could not be estimated 20 because the responses were so weak. There was a clear shift in potency and efficacy at the human α 7V274T nAChR. At the human α 7V274T nAChR, ACh and (-)-nicotine were two orders of magnitude more potent, with EC₅₀ values of 1.02 \pm 0.04 μ M and 0.94 \pm 0.12 μ M, respectively, and Hill coefficients of 1.8 \pm 0.2 and 1.3 \pm 0.2, respectively. More remarkably, 25 GTS-21 was a full agonist at the human α 7V274T nAChR with an EC₅₀ value of 4.3 \pm 0.3 μ M and a Hill coefficient of 1.5 \pm 0.1, in stark contrast to its weak partial agonist effect at the human α 7 wild type nAChR. ABT-089 also was more potent and efficacious at the human α 7V274T nAChR, with an EC₅₀ values of 28 \pm 3 μ M and a Hill coefficient of 2.3 \pm 0.4, but it was a partial agonist with an efficacy of 40 \pm 1%. These results with the human nAChR 30 subunits correlate with the 180-fold increase in ACh observed with chick α 7V251T compared to chick α 7 wild type nAChR (Galzi *et al.* (1992), *supra*). However, this is the first demonstration that the potency of (-)-nicotine also is shifted, and the first demonstration that the potency and efficacy of a partial agonists are shifted in this variant.

30 Example 3
Activation and Decay Rate of Human α 7V274T
Compared to Wild-Type Human α 7WT nAChR

35 Human α 7V274T and human α 7WT responses to EC₅₀ concentrations of ACh (1 μ M and 200 μ M, respectively) were matched for similar amplitude and are shown synchronized to

the beginning of ACh application and adjusted for equivalent baseline holding current (see Figure 4). ACh was applied to human α 7V274T for 10 sec and to human α 7WT for 2.5 sec. Brief spike-like tics near the beginning and end of the human α 7WT trace are electrical artifacts marking the opening and closing of the agonist-application valve.

5 Human α 7V274T responses activated and decayed slowly compared to the human α 7WT responses. Similarly, the analogous chick mutant nAChR activated and decayed more slowly in response to ACh (Galzi *et al.* (1992), *supra*).

Example 4

Evaluation of nAChR Antagonists for Agonist Activity at the Human α 7V274T nAChR

10 nAChR antagonists such as dihydro- β -erythroidine (DH β E), *d*-tubocurarine and hexamethonium, have been found to activate responses at chick α 7 TM-2 nAChR variants when these compounds were applied as agonists (Bertrand *et al.* (1992), *supra*). This, together with data from single-channel recording, has suggested (a) that the variants nAChRs conduct in the receptor-desensitized state and (b) that wild-type nAChR antagonists act by stabilizing the desensitized state (Bertrand *et al.* (1995), *supra*).

15 At the human α 7V274T nAChR, DH β E (10 μ M) also activated agonist-like inward current responses (see Figure 5). However, these responses were small, ranging from 2.8% to 6.9% of the response to 10 μ M ACh (Table 1) unlike the homologous chick α 7V251T nAChR where 10 μ M DH β E elicited a response 66% as large as the ACh response (Bertrand *et al.* (1993) Mutations at two distinct sites within the channel domain M2 alter calcium permeability of neuronal α 7 nicotinic receptor. *Proc. Natl. Acad. Sci. (U.S.A.)* 90:6971-6975).

20 Furthermore, at human α 7V274T this was not a general property of nAChR antagonists. Both the α 7-selective antagonist MLA (10 nM) and the nonselective nAChR antagonist mecamylamine (10 μ M) elicited the opposite effect, small inverse agonist-like outward currents ranging in amplitude from 0.9% to 12.4% of the maximal inward current response to ACh, as shown in Figure 5 and Table 1. The traces shown in Figure 5, all from a single oocyte, compare responses to mecamylamine (MEC, 10 μ M), methyllycaconitine (MLA, 10 nM), dihydro- β -erythroidine (DH β E, 10 μ M) and bathing solution (0-agonist control) applied for 20 sec each. The small 0-agonist control responses were measured in each human α 7V274T oocyte and subtracted from agonist responses when data were tabulated. Calibration lines in Figure 5 represent 10 nA and 2 sec for all traces.

Table 1

Effects of Cholinergic Antagonists at the Human α 7V274T Mutant and α 7 Wild-type nAChR

nAChR	Ligand (μ M)	% Activation ^a		% Inhibition ^b	
		10 μ M ACh	1 μ M ACh	10 μ M ACh	100 μ M ACh
α 7V274T	DH β E (10)	4 \pm 1 (4) ^c	69 \pm 5 (4) ^c	52 \pm 6 (4) ^c	
	d-TC (1)	-2 \pm 1 (4)	99 \pm 1 (4) ^c	97 \pm 3 (3) ^c	
	MLA (0.01)	-4 \pm 2 (7) ^c	103 \pm 1 (4) ^c	95 \pm 3 (7) ^c	
	MEC (10)	-1.9 \pm 0.2 (4) ^c	101 \pm 1 (4) ^c	53 \pm 2 (4) ^c	
	ATROP (2)	0.1 \pm 0.1 (4)	28 \pm 7 (5) ^c	13 \pm 5 (6) ^c	
		% of 10 mM ACh	% of 200 μ M ACh	% of 10 mM ACh	
α 7WT	DH β E (10)	-0.2 \pm 0.1 (5)	41 \pm 10 (4) ^c	23 \pm 2 (4) ^c	
	d-TC (1)	-0.1 \pm 0.1 (5)	28 \pm 2 (4) ^c	25 \pm 3 (4) ^c	
	MLA (0.01)	-0.2 \pm 0.4 (3)	100 \pm 0.5 (4)	99 \pm 0.4 (4) ^c	
	MEC (10)	-0.3 \pm 0.2 (3)	82 \pm 1 (3) ^c	85 \pm 3 (3) ^c	
	ATROP (2)	0.2 \pm 0.5 (3)	4 \pm 3 (3)	12 \pm 3 (3) ^c	

20

Abbreviations: DH β E (dihydro- β -erythroidine); d-TC (*d*-tubocurarine); MLA (methyllycaconitine); MEC (mecamylamine); ATROP (atropine).

* p < 0.05 compared to 0 (Student's two-tailed *t*-test)

† p < 0.005 compared to 0 (Student's two-tailed *t*-test)

‡ compared to activation by 10 μ M

§ % inhibition of the response to ACh

30 *d*-Tubocurarine (1 μ M) also did not elicit agonist-like inward currents, but did elicit small outward currents (3-5% of the maximal inward current response to ACh) in two of four human α 7V274T oocytes. The outward current responses may be due to stabilization of the resting (closed) state or to channel blockade of spontaneously open nAChR. At the human α 7WT nAChR under similar conditions, neither DH β E (10 μ M), MLA (10 nM), mecamylamine (10 μ M) nor *d*-tubocurarine (1 μ M) elicited any significant inward or outward current response (Table 1). The muscarinic antagonist atropine (2 μ M) alone had little effect at either nAChR.

Example 5Evaluation of nAChR Antagonists for
Agonist Activity at the Human α 7V274T nAChR

5

The above compounds also were evaluated as antagonists of the response to ACh at both human α 7V274T and human α 7WT nAChRs. For each nAChR, two concentrations of ACh were used: one near the EC₅₀ value (1 μ M for α 7V274T and 200 μ M for α 7WT) and one near the maximal response level (10 μ M for α 7V274T and 10 mM for α 7WT). Data are shown in Table 1. DH β E (10 μ M), *d*-tubocurarine (1 μ M), MLA (10 nM), and mecamylamine (10 μ M) acted as antagonists at both nAChRs. The α 7 selective antagonist MLA was particularly potent, as expected, blocking human α 7V274T as well as human α 7WT at a concentration of 10 nM. Interestingly, mecamylamine (10 μ M), DH β E (10 μ M) and *d*-tubocurarine (1 μ M) each appeared to inhibit human α 7V274T more than human α 7WT. Atropine (2 μ M) inhibited the human α 7V274T response to 1 μ M ACh by 28%, but had little effect on the human α 7WT response to 200 μ M ACh. Some oocytes have endogenous muscarinic receptors activated by low-micromolar concentrations of ACh (Kusano *et al.* (1982) *J. Physiol. (London)* 328:143-170; Davidson *et al.* (1991) *FEBS Lett.* 284:252-256; and Dascal *et al.* (1980) *Life Sci.* 27:1423-1428). However, this does not appear to explain the effect of atropine on human α 7V274T because the nAChR antagonist mecamylamine (10 μ M) completely blocked the response to 1 μ M ACh in three of the five h- α 7V274T oocytes inhibited by atropine (the other two were not exposed to mecamylamine).

DH β E (10 μ M) inhibited maximal ACh responses less strongly than it inhibited EC₅₀ ACh responses at both human α 7V274T and human α 7WT (see Table 1). Mecamylamine (10 μ M) also inhibited the maximal ACh response less strongly than the EC₅₀ ACh response at the human α 7V274T nAChR, but not at the human α 7WT nAChR where mecamylamine inhibited both concentrations of ACh similarly. The lesser inhibitions at the higher concentrations of ACh may reflect competitive antagonist-agonist interactions.

Thus, the human variant α 7V274T nAChR is similar to the analogous chick α 7V251T nAChR in its increased sensitivity to agonist activation and apparent slower rate of activation and desensitization. The receptors differ, however, in that DH β E (10 μ M) activated the human α 7V274T inward current only weakly, compared to a 66% agonist-like effect at chick α 7V251T, and in that *d*-tubocurarine did not activate inward currents at the h- α 7V274T compared to the full response at chick α 7L247T nAChR (Galzi *et al.* (1992), *supra*; Bertrand *et al.* (1993), *supra*). Thus, there may be a species difference in the effects of these sequence

modifications on $\alpha 7$ nAChR function which difference is unexpected in view of the information known regarding chick $\alpha 7V274T$.

Example 6

Human $\alpha 7V274T$ Rectification

5 The current versus voltage relationship of human $\alpha 7V274T$ variant nAChR responses to 10 μ M ACh was measured in oocytes under two-electrode voltage clamp as described by Briggs *et al.* (1995) *Neuropharmacol.* 34:583-590. This was done under two conditions: (a) 10 four oocytes in modified Barth's solution containing Ba^{2+} to prevent secondary activation of Ca^{2+} -dependent Cl^- currents (90 mM NaCl, 1 mM KCl, 0.66 mM $NaNO_3$, 10 mM $BaCl_2$, 2.5 mM sodium pyruvate, and 10 mM Na-HEPES buffer, pH 7.55) as described by Briggs *et al.* (1995), *supra*, and (b) three oocytes in OR2 solution made to replicate that used by Galzi *et al.* (1992) *Nature* 359: 500-505, in their study of chick $\alpha 7$ variants (82.5 mM NaCl, 2.5 mM KCl, 2.5 mM $CaCl_2$, 1 mM $MgCl_2$, 0.5 μ M atropine, and 5 mM Na-HEPES buffer, pH 7.4). 15 Under both conditions, clear inward rectification of the ACh response was observed in that there was little current response at cell potentials above 0 mV compared to the current response at negative cell potentials. Similarly, human $\alpha 7$ wild-type nAChR (Briggs *et al.* (1995), *supra*) and chick $\alpha 7$ wild-type nAChR (Galzi *et al.* (1992), *supra*) show inward rectification, but the 20 chick $\alpha 7V251T$ variant did not show such rectification (Galzi *et al.* (1992), *supra*).

Example 7

Expression Studies in Mammalian Cell lines

25 The human $\alpha 7$ wild-type (WT) and $\alpha 7V274T$ mutant nAChR are transfected into the human embryonic kidney cell line, HEK-293 using the eukaryotic expression vector, pRc/CMV (Invitrogen, San Diego, CA) which contains the promoter sequences from the human cytomegalovirus for high level constitutive expression and contains the neomycin 30 resistance gene for selection of geneticin-resistant stable cell lines. The cDNAs are transfected using lipofectamine (GIBCO) as described in (Gopalakrishnan *et al.* (1995) *Eur. J. Pharmacol. (Mol. Pharm.)* 290:237-246). Using this approach stable cell lines expressing the human $\alpha 7$ WT nAChR have been generated, exhibiting clear [^{125}I] α -bungarotoxin binding, acetylcholine-evoked current and Ca^{2+} influx responses (Gopalakrishnan *et al.* (1995), *supra*; Delbono *et al.* (1996) *J. Pharmacol. Exp. Ther.* (in press)). Additionally, initial data depicted 35 in Figure 7 demonstrate the feasibility of transfection of the $\alpha 7$ variant into mammalian cells.

The human α 7V274T variant bears homology to the *C. elegans* deg-3 (u662) spontaneous mutation which appears to be cytotoxic through a mechanism that is inhibited by nicotinic antagonists (Treinin and Chalfie (1995) A mutated acetylcholine receptor subunit causes neuronal degeneration in *C. elegans*. *Neuron* 14: 871-877). The human α 7V274T 5 variant nAChR response is longer lasting than wild-type responses (Figure 4) but, like chick α 7V251T variant nAChR, probably has high Ca^{2+} permeability so that activation of the receptor may, under some conditions, lead to excessive Ca^{2+} influx and thereby cell death. Further, there is some evidence that the human α 7V274T variant nAChR may be prone to 10 prolonged spontaneous opening because oocytes that have expressed α 7V274T for 3 days or longer were 10-100 fold leakier electrically than were oocytes expressing human α 7 wild-type nAChR. Thus, human α 7V274T and related variant nAChR may be cytotoxic in the presence and even in the absence of agonist. Spontaneous expression of such a variant could interfere 15 with normal α 7 nAChR function, induce premature cell death, or interfere with synapse formation. Such effects could underlie some forms of neurodegenerative diseases or other disorders involving derangement of cholinergic function.

Cytotoxicity clearly could limit the ability of cells to express the α 7V274T variant at high levels. To circumvent this, transfected cells are grown in the presence of a reversible nicotinic antagonist or channel blocker, such as methyllycaconitine or mecamylamine. Such substances would prevent cytotoxicity by blocking the receptor or channel, but could be 20 removed shortly before using the cells in further experiments.

Alternatively, the human α 7 wild type or variant is transfected using an inducible expression system such that expression of the α 7 subunit is repressed until an inducer is added. The advantage of an inducible system is that it can eliminate the cytotoxic effects of the 25 expressed protein, for example the human α 7V274T variant, that is observed when a constitutive expression system such as the pRcCMV is employed.

One of the expression vectors that is used is the LacSwitch system (Stratagene) that uses the elements of lactose operon to control gene expression. With the LacSwitch system, basal expression is very low in the repressed state and once stably transfected in cell lines, this 30 system permits rapid induction within 4-8 hours in presence of the inducing agent, IPTG. The system employs a eukaryotic Lac-repressor-expressing vector (p3'SS) and a eukaryotic lac-operator containing vector (pOPRSVI-CAT) into which the α 7 subunit construct will be inserted by cloning. Antibiotic selection is attained via the hygromycin-resistance gene in p3'SS and via the neomycin-resistance gene in pOPRSVI-CAT vector. After transfection of HEK-293 or other cells, the selection of stable cell lines is achieved by the presence of both 35 hygromycin and geneticin. Once stable cell lines are isolated, expression of the α 7 subunit will be caused by the addition of the inducing agent, IPTG. In the absence of IPTG, transcription

is blocked by the binding of the Lac repressor protein to the operator in pOPRSVI-CAT vector. IPTG decreases the binding affinity of the Lac repressor protein to the operator thereby triggering transcription and expression of the inserted α 7 subunit gene. The choice of such a system permits the direct evaluation of the role of the mutant α 7 nAChR in mediating cell death *in vitro*.

5 In Vitro Assessment of Cytotoxicity in Mammalian Cell Lines: To determine whether the human α 7V274T variant mediates cytotoxicity, cell damage can be assessed following transient expression of the cDNA in HEK-293 cells by a number of methods, for example: (i) staining the cells with Trypan blue (4%) for 5 minutes and assessing the ability of viable cells to exclude the dye; (ii) measuring the levels of the cytosolic enzyme lactate dehydrogenase (LDH) released into the medium, as an index of cell lysis (for example, Donnelly-Roberts *et al.* (1996) *Brain Res.* 719: 36-44); (iii) uptake of neutral red dye or uptake and conversion of the tetrazolium MTT as an index of viability (for example, Little *et al.* (1996) *Br. J. Dermatol.* 134: 10 199-207; D Souza *et al.* (1996) *J. Neurosci. Res.* 43: 289-298; Malcolm *et al.* (1996) *J. Neurochem.* 66: 2350-2360); (iv) uptake and binding of propidium iodide to nucleic acids (for example, Wrobel *et al.* (1996) *J. Immunol. Methods* 189: 243-249) or other techniques that are sensitive to a loss of plasma membrane integrity or cellular metabolic function. Additional techniques may be used to assess changes in nucleotide incorporation, DNA structure or integrity (for example, Alison and Sarraf (1995) *Hum. Exp. Toxicol.* 14: 234-247; Didier *et al.* (1996) *J. Neurosci.* 16: 2238-2250). These techniques are known to those of ordinary skill in the art. These studies are carried out in nontransfected or mock-transfected cells (controls), cells that are transfected with human α 7 wild-type, and cells that are transfected with human α 7V274T variant. Confirmation that human α 7V274T variant expression leads to cytotoxicity would suggest a role in triggering neurodegenerative processes *in vivo*.

15 Diagnostic application: The presence of the α 7V274T variant in humans could be determined in a non-invasive manner, for example using the polymerase chain reaction (PCR) and genomic DNA isolated from blood samples following standard methodology. Alternatively, if RNA is isolated, then reverse transcriptase-PCR ("RT-PCR") can be utilized to detect the α 7 variant. The PCR reaction, for example, could use 100 ng of the DNA in a 20 standard 50 μ l PCR reaction with the appropriate synthetic primers. The external primers used in the synthesis of the α 7 variant (X-5' and Y-3') would allow one to amplify the region of interest. The primers would be chosen to generate a distinct size fragment encompassing the sequence transmembrane segment 2, in which the V274T substitution takes place. Following amplification, the nucleotide sequence of the message is determined. The presence of the 30 variant can be an indication of cellular disease, such as neurodegeneration or other forms of cytotoxicity.

Thus, a method of detecting target polynucleotides of human variant $\alpha 7$ subunit in a test sample comprises (a) contacting a target polynucleotide of human variant $\alpha 7$ subunit with at least one human variant $\alpha 7$ subunit-specific polynucleotide probe or complement thereof; and (b) detecting the presence of the target polynucleotide and probe complex in the test sample. Another method for detecting cDNA of human $\alpha 7$ subunit mRNA in a test sample comprises (a) performing reverse transcription in order to product cDNA; (b) amplifying the cDNA obtained from step (a); and (c) detecting the presence of the human variant $\alpha 7$ subunit in the test sample. Alternatively, sampled DNA or cDNA prepared from RNA by RT-PCR can be amplified using appropriate primers (for example, X-5' and Y-3') to allow detection of the variant by nucleotide sequence analysis. The detection step (c) comprises utilizing a detectable moiety capable of generating a measurable signal.

A purified polynucleotide or fragment thereof derived from human variant $\alpha 7$ subunit capable of selectively hybridizing to the nucleic acid of human variant $\alpha 7$ subunit can be utilized in these methods, wherein said polynucleotide has a sequence comprising SEQ ID NO:1 or a portion thereof. The purified polynucleotide can be produced by recombinant techniques.

A polypeptide encoded by human variant $\alpha 7$ subunit also is useful for diagnostic applications. The polypeptide, which has an amino acid sequence comprising SEQ ID NO:2 or a portion thereof, can be produced by recombinant or synthetic techniques.

A monoclonal antibody which specifically binds to human variant $\alpha 7$ subunit can also be utilized in these methods. The human variant $\alpha 7$ subunit comprises the amino acid sequence of SEQ ID NO:2 or a portion thereof.

A method for detecting human variant $\alpha 7$ subunit in a test sample can comprise (a) contacting said test sample with an antibody or fragment thereof which specifically binds to human variant $\alpha 7$ subunit for a time and under conditions sufficient for the formation of resultant complexes; and (b) detecting said resultant complexes containing said antibody, wherein said antibody specifically binds to human variant $\alpha 7$ subunit of SEQ ID NO:2 or a fragment thereof.

Treatment application: Spontaneous mutation of human $\alpha 7$ valine-274 to threonine and related mutation could result in or hasten death of those cells expressing the protein. At least two types of treatment could be undertaken: (i) administration of a selective $\alpha 7$ antagonist such as methyllycaconitine or another compound with improved blood-brain barrier penetration; or, (ii) antisense oligonucleotide therapy to block the synthesis of the protein (for example, see Albert and Morris (1994), *Antisense knockouts: molecular scalpels for the dissection of signal transduction*. *Trends in Pharmacological Sciences* 15: 250-254); or (iii) as a reagent to kill cells such as cancer cells. For example, the antisense oligonucleotide

5'-GGCTACACCTCATGGGCTCG (SEQ ID NO:9) may be used. Thus, this oligonucleotide or others would block synthesis of any α 7 subunit protein, including wild type, but still would be of use where the variant and not the wild type is expressed, or where knockout of the wild-type is less detrimental than continued expression of the variant. The efficacy of this antisense would be demonstrated *in vitro* and, further, the antisense would be valuable as a research tool to evaluate α 7 subunit function.

10 Antisense technology can be used to reduce gene expression through triple-helix formation or antisense DNA or RNA, both of which methods are based on binding of a polynucleotide to DNA or RNA. For example, the 5' coding portion of the polynucleotide sequence, which encodes for the polypeptide of the present invention, is used to design an antisense RNA oligonucleotide of from 10 to 40 base pairs in length. A DNA oligonucleotide is designed to be complementary to a region of the gene involved in transcription thereby preventing transcription and the production of the human variant α 7 subunit polypeptide. The antisense RNA oligonucleotide hybridizes to the mRNA *in vivo* and blocks translation of an mRNA molecule into the human variant α 7 subunit polypeptide. Antisense oligonucleotides act with greater efficacy when modified to contain artificial internucleotide linkages which render the molecule resistant to nucleolytic cleavage. Such artificial internucleotide linkages include, but are not limited to, methylphosphate, phosphorothiolate and phosphoroamydate internucleotide linkages.

20 Research and drug discovery application: Antisense oligonucleotides also would be of value in determining α 7 wild-type and V274T functions, and mechanisms of cytotoxicity in general. For example, one method of evaluating the contribution of α 7V274T to cytotoxicity, cytoprotection, or other cellular processes would be to determine whether specific blockade of its synthesis blocks process. This differs in approach from the use of a receptor antagonist, 25 which may or may not block all effects of the protein. Additionally, in drug discovery this approach could be useful in evaluating whether the effect of the drug is mediated by the α 7V274T variant. A similar approach could be used to evaluate the contribution of other variants or the wild-type subunit itself. In control experiments, the corresponding α 7 sense and missense oligonucleotides 5'-CGAGCCATGAGGTGTAGCC (SEQ ID NO:10) and 30 5'-CCAGGCATTCGGAGCTTGCC (SEQ ID NO:11), respectively, are used. The missense oligonucleotide is a randomized sequence maintaining the proportion of GC content in the antisense oligonucleotide, and did not match known sequences in the GenBank database.

Thus, polynucleotides that encode novel subunit and their antisense variants of the human $\alpha 7$ nAChR can be used in a variety of ways as detailed herein. Although preferred embodiments of the subject invention have been described in some detail, it is understood that obvious variations can be made without departing from the spirit and the scope of the invention as defined by the appended claims.

What is claimed is:

1. A polynucleotide encoding a variant of a wild-type human $\alpha 7$ nicotinic acetylcholine receptor (nAChR) subunit, wherein the polynucleotide encodes a polypeptide having an amino acid substitution at position valine-274 of the wild-type human $\alpha 7$ nAChR subunit polypeptide, and degenerate variants thereof.
2. The polynucleotide of Claim 1, wherein the substitution is a threonine for valine-274.
3. A host cell comprising the polynucleotide of Claim 1.
4. The host cell of Claim 3, wherein said cell is selected from the group consisting of a bacterial cell, a mammalian cell, a yeast cell, an amphibian cell and a starfish cell.
5. An expression vector comprising the polynucleotide of Claim 1 operably linked to control sequences that direct the transcription of the polynucleotide whereby said polynucleotide is expressed in a host cell.
6. The expression vector of Claim 5, wherein the variant human $\alpha 7$ nAChR is human $\alpha 5V274T$ nAChR.
7. A host cell comprising the expression vector of Claims 5 or 6.
8. The host cell of Claim 7, wherein the cell is selected from the group consisting of a bacterial cell, a mammalian cell, a yeast cell and an amphibian cell.
9. An isolated and purified variant human $\alpha 7$ nicotinic acetylcholine receptor (nAChR) subunit, wherein the variant human $\alpha 7$ nAChR subunit comprises an amino acid substitution at position valine-274 of the wild-type human $\alpha 7$ nAChR polypeptide.
10. The variant human $\alpha 7$ receptor of Claim 9, wherein the substitution is a threonine for valine-274.

11. A method for identifying compounds that modulate nicotinic acetylcholine receptor (nAChR) activity, comprising:

- (a) providing a cell that expresses a variant human $\alpha 7$ nAChR polypeptide having an amino acid substitution at position valine-274 of the wild-type human $\alpha 7$ nAChR polypeptide;
- (b) mixing a test compound with the cell; and
- (c) measuring either
 - (i) the effect of the test compound on the variant $\alpha 7$ receptor or the cell expressing said subunit, or
 - (ii) the binding of the test compound to the cell or the receptor.

12. A method for identifying a cytoprotective compound, comprising:

- (a) providing a cell that expresses a variant human $\alpha 7$ subunit polypeptide or fragment thereof having an amino acid substitution at position valine-274 of the wild-type human $\alpha 7$ subunit polypeptide;
- (b) combining a test compound with the cell; and
- (c) monitoring the cell or cellular function for an indication of cytotoxicity.

13. A method of detecting target polynucleotides of human variant $\alpha 7$ subunit in a test sample, comprising:

- (a) contacting a target polynucleotide of human variant $\alpha 7$ subunit with at least one human variant $\alpha 7$ subunit-specific polynucleotide probe or complement thereof; and
- (b) detecting the presence of the target polynucleotide and probe complex in the test sample.

14. A purified polynucleotide or fragment thereof derived from human variant $\alpha 7$ subunit capable of selectively hybridizing to the nucleic acid of human variant $\alpha 7$ subunit wherein the sequence of said polynucleotide comprises SEQ ID NO:1 or a portion thereof, said polynucleotide being produced by recombinant techniques.

15. A polypeptide encoded by human variant $\alpha 7$ subunit polynucleotide wherein the sequence of said polypeptide comprises SEQ ID NO:2 or a portion thereof, said polypeptide being produced by recombinant or synthetic techniques.

16. A monoclonal antibody which specifically binds to human variant $\alpha 7$ subunit having the amino acid sequence of SEQ ID NO:2 or a portion thereof.




FIGURE 1

TCGAGCCC	ATG	AGG	TGT	AGC	CCC	GGG	GTG	TGG	CTG	GCA	CTG	GCA	39			
M	R	C	S	P	G	G	V	W	L	A	L	A	13			
GCA	TCT	CTG	CAC	GTG	TCC	CTG	CAA	GGC	GAG	TTC	CAG	AGG	CTT	87		
A	S	L	L	H	V	S	L	Q	G	E	F	Q	R	29		
TAC	AAG	GAG	CTG	GTC	AAG	AAC	TAC	AAT	CCC	TTG	GAG	AGG	CCC	135		
Y	K	E	L	V	K	N	Y	N	P	L	E	R	P	45		
AAT	GAC	TCG	CAA	CCA	CTC	ACC	GTC	TAC	TTC	TCC	CTG	AGC	CTC	183		
N	D	S	Q	P	L	T	V	Y	F	S	L	S	L	61		
ATC	ATG	GAC	GTG	GAT	GAG	AAG	AAC	CAA	GTT	TTA	ACC	ACC	AAC	ATT	TGG	231
I	M	D	V	D	E	K	N	Q	V	L	T	T	N	I	W	77
CTG	CAA	ATG	TCT	TGG	ACA	GAT	CAC	TAT	TTA	CAG	TGG	AAT	GTG	TCA	GAA	279
L	Q	M	S	W	T	D	H	Y	L	Q	W	N	V	S	E	93
TAT	CCA	GGG	GTG	AAG	ACT	GTT	CGT	TTC	CCA	GAT	GGC	CAG	ATT	TGG	AAA	327
Y	P	G	V	K	T	V	R	F	P	D	G	Q	I	W	K	109
CCA	GAC	ATT	CTT	CTC	TAT	AAC	AGT	GCT	GAT	GAG	CGC	TTT	GAC	GCC	ACA	375
P	D	I	L	L	Y	N	S	A	D	E	R	F	D	A	T	125
TTC	CAC	ACT	AAC	GTG	TTG	AAT	TCT	TCT	GGG	CAT	TGC	CAG	TAC	CTG	423	
F	H	T	N	V	L	V	N	S	S	G	H	C	Q	Y	L	141
CCT	CCA	GGC	ATA	TTC	AAG	AGT	TCC	TGC	TAC	ATC	GAT	GTA	CGC	TGG	TTT	471
P	P	G	I	F	K	S	S	C	Y	I	D	V	R	W	F	157
CCC	TTT	GAT	GTG	CAG	CAC	TGC	AAA	CTG	AAG	TTT	GGG	TCC	TGG	TCT	TAC	519
P	F	D	V	Q	H	C	K	L	K	F	G	S	W	S	Y	173
GGA	GGC	TGG	TCC	TTG	GAT	CTG	CAG	ATG	CAG	GAG	GCA	<u>GAT</u>	<u>ATC</u>	AGT	GGC	567
G	G	W	S	L	D	L	Q	M	Q	E	A	D	I	S	G	189

FIGURE 2A

TAT	ATC	CCC	AAT	GAA	GAA	TGG	GAC	CTA	GTC	GGA	ATC	CCC	GGC	AAG	AGG	615	
Y	I	P	N	G	E	W	D	L	V	G	I	P	G	K	R	205	
AGT	GAA	AGG	TTC	TAT	GAG	TGC	TGC	AAA	GAG	CCC	TAC	CCC	GAT	GTC	ACC	663	
S	E	R	F	Y	E	C	C	K	E	P	Y	P	D	V	T	221	
TTC	ACA	GTG	ACC	ATG	CGC	CGC	AGG	ACA	CTC	TAC	TAT	GGC	CTC	AAC	CTG	711	
F	T	V	T	M	R	R	T	L	Y	G	L	N	L	N	L	237	
CTG	ATC	CCC	TGT	GTG	CTC	ATC	TCC	GCC	CTC	GCC	CTG	CTG	CTG	TTC	CTG	759	
L	I	P	C	V	L	I	S	A	L	A	L	L	V	F	L	253	
CTT	CCT	GCA	GAT	TCC	GGG	GGG	GAG	AAG	ATT	TCC	CTG	GGG	ATA	ACA	GTC	TTA	807
L	P	A	D	S	G	E	K	I	S	L	G	I	T	V	L	269	
274	CTC	TCT	CTT	ACC	ACC	TTC	ATG	CTG	CTC	GTC	GCT	GAG	ATC	ATG	CCC	GCA	
L	S	L	T	T	F	M	L	L	V	A	E	I	M	P	A	855	
ACA	TCC	GAT	TCG	<u>GTA</u>	<u>CCA</u>	TTG	ATA	GCC	CAG	TAC	TTC	GCC	AGC	ACC	ATG	903	
T	S	D	S	V	P	L	I	A	Q	Y	F	A	S	T	M	301	
ATC	ATC	GTG	GGC	CTC	TCG	GTG	GTG	ACG	GTG	ATC	GTG	CTG	CAG	TAC	951		
I	I	V	G	L	S	V	V	T	V	I	V	L	Q	Y	317		
CAC	CAC	GAC	CCC	GAC	GCC	GGC	AAG	ATG	CCC	AAG	TGG	ACC	AGA	GTC	999		
H	H	D	P	D	G	G	K	M	P	K	W	T	R	V	333		
ATC	CTT	CTG	AAC	TGG	TGC	GGC	TGG	TTC	CTG	CGA	ATG	AAG	AGG	CCC	GGG	1047	
I	L	L	N	W	C	A	W	F	L	R	M	K	R	P	G	349	
GAG	GAC	AAG	GTG	CGC	CGC	GCC	TGC	CAG	CAC	AAG	CAG	CGG	CGC	TGC	AGC	1095	
E	D	K	V	R	P	A	C	Q	H	K	Q	R	R	C	S	350	
CTG	GCC	AGT	GTG	GAG	ATG	AGC	GCC	GTG	GGC	CCG	CCC	GCC	AGC	AAC	1143		
L	A	S	V	E	M	S	A	V	A	P	P	A	S	N	366		

FIGURE 2B

GGG	AAC	CTG	CTG	TAC	ATC	GGC	TTC	CGC	CTG	GAC	GGC	GTG	CAC	TGT	1191	
G	N	L	L	Y	I	G	F	R	G	L	D	G	V	H	C	382
GTC	CCG	ACC	CCC	GAC	TCT	GGG	GTA	GTG	TGT	GGC	CGC	ATG	GCC	TGC	TCC	1239
V	P	T	P	D	S	G	V	V	C	G	R	M	A	C	S	398
CCC	ACG	CAC	GAT	GAG	CAC	CTC	CTG	CAC	GGC	GGG	CAA	CCC	GAG	GGG	1287	
P	T	H	D	E	H	L	L	H	G	G	Q	P	P	E	G	414
GAC	CCG	GAC	TTG	GCC	AAG	ATC	CTG	GAG	GAG	GTC	CGC	TAC	ATT	GCC	AAC	1335
D	P	D	L	A	K	I	L	E	E	V	R	Y	I	A	N	430
CGC	TTC	CGC	TGC	CAG	GAC	GAA	AGC	GAG	GGG	GTC	TGC	AGC	TGG	AAG	1383	
R	F	R	C	Q	D	E	S	E	A	V	C	S	E	W	K	446
TTC	GCC	GCC	TGT	GTG	GTG	GAC	CGC	CTG	TGC	CTC	ATG	GCC	TTC	TCG	GTC	1431
F	A	A	C	V	V	D	R	L	C	L	M	A	F	S	V	462
TTC	ACC	ATC	TGC	ACC	ATC	GGC	ATC	CTG	ATG	TCG	GCT	CCC	AAC	TTC	1479	
F	T	I	I	C	T	I	G	I	L	M	S	A	P	N	F	478
GTG	GAG	GCC	GTG	TCC	AAA	GAC	TTT	GCG	TAACCACGGCTGGTTCTGTACATGTGG							
V	E	A	V	S	K	D	F	A								

AAA
AAACTCACAGATGGCAAGCGCTTGGCTTGGGATTGGGGAA

5/9




FIGURE 3




FIGURE 4




FIGURE 5




FIGURE 6




FIGURE 7



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/12, 15/11, 15/85, C07K 14/47, C12P 21/08, G01N 33/566		A3	(11) International Publication Number: WO 98/28331 (43) International Publication Date: 2 July 1998 (02.07.98)
<p>(21) International Application Number: PCT/US97/23405</p> <p>(22) International Filing Date: 22 December 1997 (22.12.97)</p> <p>(30) Priority Data: 08/771,737 20 December 1996 (20.12.96) US</p> <p>(71) Applicant: ABBOTT LABORATORIES [US/US]; CHAD 0377/AP6D-2, 100 Abbott Park Road, Abbott Park, IL 60064-3500 (US).</p> <p>(72) Inventors: BRIGGS, Clark, A.; 2280 Shannondale, Libertyville, IL 60048 (US). GOPALAKRISHNAN, Murali; 1568 Oxford Circle, Grayslake, IL 60030 (US). MCKENNA, David, G.; 3404 Cove court, McHenry, IL 60050 (US). MONTEGGIA, Lisa, M.; Apartment 2A, 239 Dittmer, Lindenhurst, IL 60046 (US). ROCH, Jean-Marc; Apartment 109, 1020 Lakehurst Drive, Waukegan, IL 60085 (US). SULLIVAN, James, P.; 705 Dimmeydale Drive, Deerfield, IL 60015 (US). TOUMA, Edward; 3313 Beacon Street #204, North Chicago, IL 60064 (US).</p> <p>(74) Agents: DANCKERS, Andreas, M. et al.; Abbott Laboratories, CHAD 0377/AP6D-2, 100 Abbott Park Road, Abbott Park, IL 60064-3500 (US).</p>		<p>(81) Designated States: CA, JP, MX, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p> <p>(88) Date of publication of the international search report: 5 November 1998 (05.11.98)</p>	
<p>(54) Title: A VARIANT HUMAN ALPHA-7 ACETYLCHOLINE RECEPTOR SUBUNIT, AND METHODS OF PRODUCTION AND USE THEREOF</p> <p>(57) Abstract</p> <p>A variant human $\alpha 7$ nicotinic acetylcholine receptor (nAChR) polypeptide is provided wherein the variant contains an amino acid substitution at the valine-274 position of the wild-type human $\alpha 7$ nAChR. Nucleic acid molecules encoding the variant human $\alpha 7$ nAChR, vectors and host cells containing such nucleic acid molecules are also provided. In addition, methods are provided for producing the variant as are methods of using such variants for screening compounds for activity at the nAChR.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 97/23405

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6	C12N15/12	C12N15/11	C12N15/85	C07K14/47	C12P21/08
G01N33/566					

According to International Patent Classification(IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category ^a	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 94 20617 A (THE SALK INSTITUTE BIOTECHNOLOGY/INDUSTRIAL ASSOCIATES, INC.) 15 September 1994 see page 4, line 26 – page 7, line 17 see page 14, line 7 – page 15, line 2 see page 17, line 4 – page 19, line 2 see page 29, line 34 – page 30, line 27 see page 32, line 19 – page 33, line 3 see Sequence Listing: SEQ ID NO: 7 AND 8 see claims 1,6-9,29,43 ----	14-16
A	-/-	1-13

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

7 September 1998

23/09/1998

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Donath, C

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 97/23405

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	PENG, X. ET AL.: "Human alpha 7 acetylcholine receptor: Cloning of the alpha 7 subunit from the SH-SY5Y cell line and determination of pharmacological properties of native receptors and functional alpha 7 homomers expressed in <i>Xenopus</i> oocytes" MOLECULAR PHARMACOLOGY, vol. 45, no. 3, March 1994, pages 546-554, XP002076578 see 'Materials and Methods' see page 549, right-hand column, paragraph 1 - page 552, left-hand column, paragraph 2; figures 2,3 ---	14-16
X	ELLIOTT, K.J. ET AL.: "Comparative structure of human neuronal alpha 2 - alpha 7 and B2 - B4 nicotinic acetylcholine receptor subunits and functional expression of the alpha 2, alpha 3, alpha 4, alpha 7, B2, and B4 subunits" JOURNAL OF MOLECULAR NEUROSCIENCE, vol. 7, 1996, pages 217-228, XP002076579 see the whole document	14,15
A	---	1-13,16
Y	TREININ M. AND CHALFIE M.: "A mutated acetylcholine receptor subunit causes neuronal degeneration in <i>C.elegans</i> " NEURON, vol. 14, no. 4, April 1995, pages 871-877, XP002076580 see the whole document	1-16
Y	GALZI, J.-L. AND CHANGEUX, J.-P.: "Review: Neurotransmitter Receptors VI; Neuronal nicotinic receptors: molecular organization and regulations" NEUROPHARMACOLOGY, vol. 34, no. 6, 1995, pages 563-582, XP002076581 cited in the application see page 567, right-hand column, paragraph 3 - page 569, left-hand column, paragraph 2 see page 571, left-hand column, paragraph 2 - right-hand column, last paragraph; figures 4,5 ---	1-16
	-/-	

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 97/23405

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	BERTRAND, D. ET AL.: "Mutations at two distinct sites within the channel domain M2 alter calcium permeability of neuronal alpha 7 nicotinic receptor" PROC.NATL.ACAD.SCI.USA, vol. 90, August 1993, pages 6971-6975, XP002076582 cited in the application see the whole document -----	1-16

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 97/23405

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9420617	A 15-09-1994	AU	694424 B	23-07-1998
		AU	6517394 A	26-09-1994
		CA	2155330 A	15-09-1994
		EP	0688361 A	27-12-1995
		GB	2286397 A, B	16-08-1995
		GB	2308121 A, B	18-06-1997
		JP	8507441 T	13-08-1996